ES2721922T3 - Tratamiento o prevención del daño neuronal no inflamatorio por traumatismo cerebral e ictus utilizando mentol, linalool y/o icilina - Google Patents

Tratamiento o prevención del daño neuronal no inflamatorio por traumatismo cerebral e ictus utilizando mentol, linalool y/o icilina Download PDF

Info

Publication number
ES2721922T3
ES2721922T3 ES14726347T ES14726347T ES2721922T3 ES 2721922 T3 ES2721922 T3 ES 2721922T3 ES 14726347 T ES14726347 T ES 14726347T ES 14726347 T ES14726347 T ES 14726347T ES 2721922 T3 ES2721922 T3 ES 2721922T3
Authority
ES
Spain
Prior art keywords
linalool
stroke
treatment
icilin
menthol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14726347T
Other languages
English (en)
Spanish (es)
Inventor
Susana Camacho
Gonzalez Stéphanie Michlig
Coutre Johannes Le
Henry Markram
Maurizio Pezzoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Application granted granted Critical
Publication of ES2721922T3 publication Critical patent/ES2721922T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES14726347T 2013-05-24 2014-05-23 Tratamiento o prevención del daño neuronal no inflamatorio por traumatismo cerebral e ictus utilizando mentol, linalool y/o icilina Active ES2721922T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361827232P 2013-05-24 2013-05-24
PCT/EP2014/060637 WO2014187945A1 (en) 2013-05-24 2014-05-23 Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using menthol, linalool and/or icilin

Publications (1)

Publication Number Publication Date
ES2721922T3 true ES2721922T3 (es) 2019-08-06

Family

ID=50819728

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14726347T Active ES2721922T3 (es) 2013-05-24 2014-05-23 Tratamiento o prevención del daño neuronal no inflamatorio por traumatismo cerebral e ictus utilizando mentol, linalool y/o icilina

Country Status (10)

Country Link
US (2) US20160166570A1 (enExample)
EP (1) EP3003292B1 (enExample)
JP (2) JP2016520588A (enExample)
CN (1) CN105228601A (enExample)
AU (2) AU2014270341A1 (enExample)
BR (1) BR112015026484A2 (enExample)
CA (1) CA2908365C (enExample)
ES (1) ES2721922T3 (enExample)
TR (1) TR201906539T4 (enExample)
WO (1) WO2014187945A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520588A (ja) * 2013-05-24 2016-07-14 ネステク ソシエテ アノニム メントール、リナロール及び／又はイシリンを用いる脳外傷及び卒中からの非炎症性ニューロン傷害の処置又は予防
JP7641973B2 (ja) * 2020-03-24 2025-03-07 中国▲医▼薬大学 神経変性疾患及び脳卒中を改善する外用組成物の調製に用いられるメントールの用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL164828A0 (en) * 2002-04-25 2005-12-18 Brainsgate Ltd Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
JP4742204B2 (ja) * 2005-01-21 2011-08-10 財団法人ヒューマンサイエンス振興財団 脂肪細胞分化制御剤
JP2007291069A (ja) * 2006-03-31 2007-11-08 Daiichi Sankyo Healthcare Co Ltd 抗酸化剤および／または消炎鎮痛剤組成物
GB0615136D0 (en) * 2006-07-29 2006-09-06 Univ Edinburgh Induction of analgesia in neuropathic pain
KR20090085237A (ko) * 2008-02-04 2009-08-07 김병문 천연 진주가루를 함유한 뇌질환 예방 및 치료용 한약조성물
WO2011006073A1 (en) * 2009-07-10 2011-01-13 President And Fellows Of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
KR20120103317A (ko) * 2011-03-10 2012-09-19 한국생명공학연구원 아실 코에이:콜레스테롤 아실트랜스퍼라제 저해활성을 갖는 고수씨 추출물 또는 이로부터 분리된 리나로올을 포함하는 조성물
US9585875B2 (en) * 2011-12-19 2017-03-07 Dompé Farmaceutici S.P.A. TRPM8 antagonists
CN102512634A (zh) * 2011-12-26 2012-06-27 神威药业（张家口）有限公司 复方麝香软胶囊及其制备方法
WO2013168090A1 (en) * 2012-05-07 2013-11-14 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Researc Organization (Aro) (Volcanii Center). Geranium oil and constituents thereof for treatment of neurodegenerative diseases
JP2016520588A (ja) * 2013-05-24 2016-07-14 ネステク ソシエテ アノニム メントール、リナロール及び／又はイシリンを用いる脳外傷及び卒中からの非炎症性ニューロン傷害の処置又は予防

Also Published As

Publication number Publication date
WO2014187945A1 (en) 2014-11-27
CN105228601A (zh) 2016-01-06
CA2908365C (en) 2023-02-28
JP2016520588A (ja) 2016-07-14
AU2014270341A1 (en) 2015-10-08
JP2020011985A (ja) 2020-01-23
EP3003292B1 (en) 2019-03-20
AU2019222781B2 (en) 2021-05-13
CA2908365A1 (en) 2014-11-27
BR112015026484A2 (pt) 2017-07-25
TR201906539T4 (tr) 2019-05-21
US10799502B2 (en) 2020-10-13
EP3003292A1 (en) 2016-04-13
US20170189403A1 (en) 2017-07-06
US20160166570A1 (en) 2016-06-16
AU2019222781A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
NI201500140A (es) Compuestos y composiciones terapéuticos
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
MX2016006623A (es) Compuestos de inhibidor de autotaxina.
DOP2016000253A (es) Nuevos compuestos
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CL2016001151A1 (es) Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
MX2016005446A (es) Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel